Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Maeve Aine Lowery

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-1354-7606; OpenAlex author ID A5057803141; NIH RePORTER profile ID 10605564. Sources: ClinicalTrials.gov.

Their work

Papers
35 (first author 5, last author 1)
Trials
1 (principal investigator on 1)
Grants
1
Labs led
0
Collaborators
95
Papers, trials and grants by year

2011: 4 papers · 2012: 4 papers · 2013: none · 2014: 3 papers, 1 trial · 2015: 5 papers · 2016: 2 papers · 2017: 5 papers · 2018: 6 papers · 2019: 1 paper, 1 grant · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: 1 paper

Papers 35

  1. Mechanisms of Resistance to PARPi in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/jcmm.70816↗
  2. Moving the Needle on Precision Medicine in Pancreatic Cancer. First author DOI 10.1200/jco.21.02514↗
  3. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Co-author DOI 10.3389/fcell.2021.749490↗
  4. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-l… Last author DOI 10.1007/s10637-019-00830-3↗
  5. Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer. Co-author DOI 10.1038/s41416-019-0645-9↗
  6. Genomic Landscape of Pancreatic Adenocarcinoma in Younger versus Older Patients: Does Age Matter? Co-author DOI 10.1158/1078-0432.ccr-18-3042↗
  7. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adeno… Co-author DOI 10.1002/cncr.31218↗
  8. Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. Co-author DOI 10.1016/j.clcc.2017.12.001↗
  9. Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.clcc.2018.01.008↗
  10. Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? First author DOI 10.1016/j.clcc.2018.01.009↗
  11. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  12. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers10120467↗
  13. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.30897↗
  14. In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetic… Co-author DOI 10.1007/s11307-017-1078-6↗
  15. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Co-author DOI 10.1080/0284186x.2017.1342863↗
  16. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  17. Preliminary study of tumor heterogeneity in imaging predicts two year survival in pancreatic cancer patients. Co-author DOI 10.1371/journal.pone.0188022↗
  18. Current management and future directions in metastatic pancreatic adenocarcinoma. First author DOI 10.1002/cncr.30342↗
  19. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. First author DOI 10.1586/17474124.2016.1153424↗
  20. Identification of germline genetic mutations in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29664↗
  21. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior ther… Co-author DOI 10.1016/j.ejca.2015.06.119↗
  22. Novel Therapeutics for Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.hoc.2015.04.006↗
  23. Reverse-Contrast Imaging and Targeted Radiation Therapy of Advanced Pancreatic Cancer Models. Co-author DOI 10.1016/j.ijrobp.2015.06.001↗
  24. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4647-4↗
  25. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage I… Co-author DOI 10.1016/j.pan.2014.07.003↗
  26. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-14-0531↗
  27. Treatment of metastatic pancreatic adenocarcinoma: new options and promising strategies. Co-author PMID 24683722↗
  28. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Co-author DOI 10.1038/tpj.2011.52↗
  29. Postresection surveillance for pancreatic cancer performance status, imaging, and serum markers. First author DOI 10.1097/ppo.0b013e3182758e27↗
  30. A case of synchronous pancreatic ductal adenocarcinoma and ovarian mucinous cystic neoplasm: use of kras mutation molecular phenotyping to demonstrate independ… Co-author PMID 22690261↗
  31. Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma. Co-author PMID 23077687↗
  32. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. Co-author DOI 10.1007/s12029-010-9197-1↗
  33. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Co-author DOI 10.1634/theoncologist.2011-0185↗
  34. New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. Co-author DOI 10.2165/11592470-000000000-00000↗
  35. Pancreatic cancer: the role of molecular markers in diagnosis and management. Co-author PMID 22252658↗

Trials 1

  1. Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer Principal investigator NCT02101580↗

Grants 1

  1. Imaging drug uptake and distribution in chemoradiation therapy of pancreatic cancer R01CA194321↗

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 29 shared papers, 2011–2020 · strength 1.77
  2. Kenneth H. Yu · 15 shared papers, 1 shared grant, 2011–2019 · strength 1.19
  3. Naomi Walsh · 2 shared papers, 2021–2025 · strength 0.47
  4. Jojanneke Stoof · 2 shared papers, 2021–2025 · strength 0.47
  5. Anna M. Varghese · 5 shared papers, 2016–2018 · strength 0.37
  6. John Laurence Humm · 2 shared papers, 1 shared grant, 2015–2019 · strength 0.37
  7. David Paul Kelsen · 7 shared papers, 2011–2018 · strength 0.33
  8. Grainne Mary O'Kane · 1 shared paper, 2022 · strength 0.33
  9. Nagavarakishore Pillarsetty · 1 shared paper, 1 shared grant, 2017–2019 · strength 0.32
  10. Christine A. Iacobuzio–Donahue · 4 shared papers, 2016–2019 · strength 0.27
  11. Marinela Capanu · 4 shared papers, 2017–2018 · strength 0.26
  12. Peter J. Allen · 5 shared papers, 2011–2018 · strength 0.26
  13. Zsofia Kinga Stadler · 5 shared papers, 2011–2018 · strength 0.26
  14. Erin E. Salo‐Mullen · 5 shared papers, 2011–2018 · strength 0.26
  15. Ghassan K. Abou‐Alfa · 5 shared papers, 2012–2018 · strength 0.25
  16. Abraham Wu · 1 shared grant, 2019 · strength 0.25
  17. Karyn A. Goodman · 3 shared papers, 2015–2019 · strength 0.20
  18. Richard Kinh Gian · 3 shared papers, 2015–2018 · strength 0.20
  19. Leonard B. Saltz · 4 shared papers, 2014–2018 · strength 0.19
  20. Andrew S. Epstein · 4 shared papers, 2011–2018 · strength 0.16
  21. Steven D Leach · 2 shared papers, 2017–2019 · strength 0.14
  22. İbrahim Halil Şahin · 2 shared papers, 2016–2018 · strength 0.13
  23. David P. Ryan · 2 shared papers, 2014–2020 · strength 0.13
  24. William R. Jarnagin · 3 shared papers, 2012–2017 · strength 0.13
  25. Olca Baştürk · 2 shared papers, 2017–2018 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.